AnaptysBio (NASDAQ:ANAB) Receives “Outperform” Rating from Wedbush

AnaptysBio (NASDAQ:ANAB)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research report issued to clients and investors on Monday,RTT News reports. They currently have a $40.00 price target on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 131.88% from the stock’s current price.

A number of other equities analysts have also recently issued reports on ANAB. Guggenheim cut their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Wells Fargo & Company cut their price target on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. UBS Group boosted their target price on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. dropped their price target on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and an average target price of $41.45.

AnaptysBio Stock Down 3.8 %

Shares of AnaptysBio stock traded down $0.68 during trading hours on Monday, hitting $17.25. 20,757 shares of the company’s stock traded hands, compared to its average volume of 655,665. The stock has a 50 day simple moving average of $17.38 and a 200-day simple moving average of $27.06. The company has a market cap of $524.92 million and a PE ratio of -2.84. AnaptysBio has a twelve month low of $12.51 and a twelve month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.72) by $0.58. The company had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, equities research analysts predict that AnaptysBio will post -6.08 EPS for the current year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc acquired 6,646 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was purchased at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the acquisition, the director now owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 33.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AnaptysBio

A number of large investors have recently bought and sold shares of ANAB. FMR LLC boosted its holdings in AnaptysBio by 15.3% in the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after purchasing an additional 438,557 shares in the last quarter. Jennison Associates LLC bought a new stake in AnaptysBio in the third quarter worth $8,874,000. Victory Capital Management Inc. boosted its holdings in AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after purchasing an additional 206,750 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after acquiring an additional 168,813 shares during the period. Finally, Walleye Capital LLC bought a new stake in AnaptysBio during the third quarter valued at about $5,494,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.